No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014

Affiliations

¹ Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. Electronic address: lars.wallentin@ucr.uu.se.
² Division of Cardiovascular Health and Disease, Heart, Lung and Vascular Institute, Academic Health Center, Cincinnati, OH, USA.
³ Cardiovascular Division, Brigham and Women's Hospital, Harvard Clinical Research Institute, Boston MA, USA.
⁴ Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
⁵ AstraZeneca Research and Development, Mölndal, Sweden.
⁶ Medical Department, Hospital Unit West, Herning/Holstbro, Denmark.
⁷ Medizinishe Klinik, Universitätsklinikum Heidelberg, Heidelberg, Germany.
⁸ Department of Medicine, Stanford University, Stanford, CA, USA.
⁹ Duke Clinical Research Institute, Duke University, Medical Center, Durham, NC, USA.
¹⁰ Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom.
¹¹ INSERM-Unité, 1148, Paris, France; Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France; Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France; NHLI Imperial College, ICMS, Royal Brompton Hospital, London, UK.

Comment

Lars Wallentin et al. Int J Cardiol. 2014 Sep.

. 2014 Sep;176(1):300-2.

doi: 10.1016/j.ijcard.2014.06.029. Epub 2014 Jun 27.

¹ Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. Electronic address: lars.wallentin@ucr.uu.se.
² Division of Cardiovascular Health and Disease, Heart, Lung and Vascular Institute, Academic Health Center, Cincinnati, OH, USA.
³ Cardiovascular Division, Brigham and Women's Hospital, Harvard Clinical Research Institute, Boston MA, USA.
⁴ Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
⁵ AstraZeneca Research and Development, Mölndal, Sweden.
⁶ Medical Department, Hospital Unit West, Herning/Holstbro, Denmark.
⁷ Medizinishe Klinik, Universitätsklinikum Heidelberg, Heidelberg, Germany.
⁸ Department of Medicine, Stanford University, Stanford, CA, USA.
⁹ Duke Clinical Research Institute, Duke University, Medical Center, Durham, NC, USA.
¹⁰ Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom.
¹¹ INSERM-Unité, 1148, Paris, France; Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France; Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France; NHLI Imperial College, ICMS, Royal Brompton Hospital, London, UK.

No abstract available

Comment on

Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel.
DiNicolantonio JJ, Tomek A. DiNicolantonio JJ, et al. Int J Cardiol. 2013 Oct 30;169(2):145-6. doi: 10.1016/j.ijcard.2013.08.085. Epub 2013 Sep 7. Int J Cardiol. 2013. PMID: 24120213
Discrepancies in the primary PLATO trial publication and the FDA reviews.
Serebruany VL. Serebruany VL. Int J Cardiol. 2014 Mar 1;172(1):8-10. doi: 10.1016/j.ijcard.2013.12.025. Epub 2013 Dec 22. Int J Cardiol. 2014. PMID: 24456868